Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum β-lactamase

Journal of Medical Microbiology

Volumn 59, Issue 1, 2010, Pages 115-119

  Skurnik, David ^a,d   Lasocki, Sigismond ^a   Bremont, Sylvie ^b   Muller Serieys, Claudette ^a   Kitzis, Marie Dominique ^c   Courvalin, Patrice ^b   Andremont, Antoine ^a   Montravers, Philippe ^a  

^a BICHAT HOSPITAL   (France)

^b INSTITUT PASTEUR   (France)

^c SAINT JOSEPH HOSPITAL   (France)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL PROTEIN; CATECHOLAMINE; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CIPROFLOXACIN; CLOXACILLIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PORIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CONJUGATION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CARDIOGENIC SHOCK; CASE REPORT; CONTROLLED STUDY; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; GENE SEQUENCE; GRAND MAL SEIZURE; HUMAN; KLEBSIELLA INFECTION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MEDIASTINITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RIBOTYPING; SEQUENCE ANALYSIS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MEDIASTINITIS; MIDDLE AGED; SURGICAL WOUND INFECTION; TIME FACTORS;

EID: 73649094089     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.012468-0     Document Type: Article

References (17)

1. Boyer, H. W. & Roulland-Dussoix, D. A. (1969). Complementation analysis of the restriction and modification of DNA in Escherichia coli. J Mol Biol 41, 459-472.
2. DiNubile, M. J., Chow, J. W., Satishchandran, V., Polis, A., Motyl, M. R., Abramson, M. A. & Teppler, H. (2005). Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother 49, 3217-3221.
3. Doumith, M., Ellington, M. J., Livermore, D. M. & Woodford, N. (2009). Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J Antimicrob Chemother 63, 659-667.
4. Elliott, E., Brink, A. J., van Greune, J., Els, Z., Woodford, N., Turton, J., Warner, M. & Livermore, D. M. (2006). In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 42, e95-e98.
5. Hernandez-Alles, S., Albert, S., Alvarez, D., Domenech-Sanchez, A., Martinez-Martinez, L., Gil, J., Thomas, J. M. & Benedil, V. J. (1999). Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 145, 673-679.
6. Landman, D., Bratu, S. & Quale, J. (2009). Contribution of OmpK36 to carbapenem susceptibility in KPC-producing Klebsiella pneumoniae. J Med Microbiol 58, 1303-1308.
7. Leavitt, A., Chmelnitsky, I., Colodner, R., Ofek, I., Carmeli, Y. & Navon-Venezia, S. (2009). Ertapenem resistance among extended-spectrum-β-lactamase-producing Klebsiella pneumoniae. J Clin Microbiol 47, 969-974.
8. Livermore, D. M., Sefton, A. M. & Scott, G. M. (2003). Properties and potential of ertapenem. J Antimicrob Chemother 52, 331-344.
9. Martínez-Martínez, L., Pascual, A., Hernández- Allés, S., Alvarez-Díaz, D., Suárez, A. L., Tran, J., Benedí, V. J. & Jacoby, G. A. (1999). Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 43, 1669-1673.
10. Roy, S., Higareda, I., Angel-Muller, E., Ismail, M., Hague, C., Adeyi, B., Woods, G. L., Teppler, H. & Protocol 023 Study Group (2003). Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol 11, 27-37.
11. Schwaber, M. J., Navon-Venezia, S., Schwartz, D. & Carmeli, Y. (2005). High levels of antimicrobial coresistance among extended-spectrum- β-lactamase producing Enterobacteriaceae. Antimicrob Agents Chemother 49, 2137-2139.
12. Shah, P. M. & Isaacs, R. D. (2003). Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 52, 538-542.
13. Solomkin, J. S., Yellin, A. E., Rotstein, O. D., Christou, N. V., Dellinger, E. P., Tellado, J. M., Malafaia, O., Fernandez, A., Choe, K. A. & other authors (2003). Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237, 235-245.
14. Tenover, F. C., Arbeit, R. D., Goering, R. V., Mickelsen, P. A., Murray, B. E., Persing, D. H. & Swaminathan, B. (1995). Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33, 2233-2239.
15. Wang, X. D., Cai, J. C., Zhou, H. W., Zhang, R. & Chen, G. X. (2009). Reduced susceptibility to carbapenems in Klebsiella pneumoniae clinical isolates associated with plasmid-mediated β-lactamase production and OmpK36 porin deficiency. J Med Microbiol 58, 1196-1202.
16. Yellin, A. E., Hassett, J. M., Fernandez, A., Geib, J., Adeyi, B., Woods, G. L., Teppler, H. & The 004 Intra-Abdominal Infection Study Group (2002). Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intraabdominal infections in adults. Int J Antimicrob Agents 20, 165-173.
17. Yellin, A. E., Johnson, J., Higareda, I., Congeni, B. L., Arrieta, A. C., Fernsler, D., West, J. & Gesser, R. (2007). Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. Am J Surg 194, 367-374.